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Summary
 Background: The enzyme coproporphyrinogen oxidase (copro’gen oxidase) converts coproporphyrinogen-III 
(C-III) to protoporphyrinogen-IX via an intermediary monovinyl porphyrinogen. The A ring iso-
mer coproporphyrinogen-IV (C-IV) has previously been shown to be a substrate for copro’gen ox-
idase derived from avian erythrocytes. In contrast to the authentic substrate (C-III) where only a 
small amount of the monovinyl intermediate is detected, C-IV gives rise to a monovinyl interme-
diate that accumulates before being converted to an isomer of protoporphyrinogen-IX. No kinet-
ic studies have been carried out using the purifi ed human copro’gen oxidase to evaluate its abili-
ty to process both the authentic substrate as well as analogs.
 Materials/Methods: Therefore, purifi ed, cloned human copro’gen oxidase was incubated with C-III or C-IV at 37oC 
with various substrate concentrations (from 0.005 µM to 3.5 µM). The Km (an indication of mo-
lecular recognition) and Kcat (turnover number) values were determined.
 Results: The Km value for total product formation was about the same with either C-III or C-IV indicating 
the same molecular recognition. However, the catalytic effi ciency (Kcat/Km) of the enzyme for to-
tal product formation was not more than two fold higher using C-III relative to C-IV.
 Conclusions: Since the Km values are about the same for either substrate and the total Kcat/Km values are within 
two fold of each other, this could correlate with the increase of severity of porphyrias with monovi-
nyl accumulation. The ability of the increased levels of C-IV to compete with the authentic sub-
strate has important implications for clinical porphyrias.
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BACKGROUND
Porphyrias are a group of clinical disorders, either genet-
ic or acquired, that are characterized by accumulation of 
one or more type of porphyrins in tissues as well as high-
er levels of excretion in the urine and/or feces. These 
patients are generally characterized with mild to severe 
mental retardation, photosensitivity, and problems in 
the liver and/or bone marrow. Thus, understanding the 
enzymes involved in the heme biosynthesis pathway and 
their ability to process both the authentic substrates and 
analogs of these substrates is important in helping to devel-
op clinical therapies for porphyrias. Defects in the various 
enzymes of the synthetic pathway have been correlated with 
various classes of porphyrias but much work yet remains.
Coproporphyrinogen oxidase (copro’gen oxidase; EC 
1.3.3.3) is the sixth enzyme in the biosynthetic pathway for 
the production of heme. Coproporphyrinogen-III (C-III), 
the authentic substrate for the enzyme copro’gen oxidase, 
undergoes two sequential oxidative decarboxylations at the 
A and B ring propionates to produce fi rst a monovinyl prod-
uct and then a divinyl product (Figure 1A).
Harderoporphyria is a disorder often characterized by an 
accumulation of monovinyl porphyrins in the body and 
considered to be related to mutations in the gene encod-
ing copro’gen oxidase. In addition, C-III and its isomer co-
proporphyrinogen-IV (C-IV) have been isolated from these 
types of patients [1]. Yet, C-IV also has been reported in the 
urine of patients with a defect in the enzyme 5-aminolevulin-
ic acid dehydratase [2]. Kühnel et al. [1] also reported the 
presence of C-IV in the urine of normal people, although 
in much lower amounts.
Modifi ed porphyrinogens have been used to probe the ac-
tive site of copro’gen oxidase. C-IV was fi rst found to be a 
substrate for ox-liver copro’gen oxidase by Porra and Falk 
in 1964 [3], and was subsequently shown to be converted 
to protoporphyrinogen-XIII via a monovinyl intermediate 
(Figure 1B). Jackson et al., using crude enzyme preparations 
from chicken red blood cells, reported that the monovinyl 
intermediate from C-IV accumulated to about 40% total 
porphyrinogen at intermediary incubation times, but was 
eventually converted to the divinyl product [4]. This con-
trasts to time study experiments with authentic C-III where 
accumulation of the monovinyl species, harderoporphyrin-
ogen, was less than 10%. In addition, Buldain et al. showed 
that incubations of C-IV with crude copro’gen oxidase prep-
arations from duck blood, chicken blood and beef liver gave 
divinyl product at a rate of only 10% that of C-III [5]. These 
studies also showed that the type isomers coproporphyrin-
ogen-I and coproporphyrinogen-II were not substrates for 
copro’gen oxidase. On the bases of these and other inves-
tigations with substrate analogs [6–9], Lash et al. proposed 
a substrate recognition model for the enzyme [10]. In this 
model, there are requirements for the correct sequence of 
the peripheral substituents around the macrocycle. In or-
der to provide the correct “fi t”, the sequence R Me-P Me-P 
is required, where Me= –CH3, P= –CH2CH2CO2H and R is a 
small nonpolar grouping such as Me, ethyl, or vinyl. When 
C-III is metabolized, a vinyl group is generated at ring A. 
The model predicts that the substrate remains in the active 
site and can rotate through 90o and present the active site 
with the correct sequence of substituents for the second “B 
ring” propionate group to undergo oxidative decarboxyla-
tion. The Lash et al. paper also models the active site with 
C-IV leaving the active site and re-entering prior to the sec-
ond oxidative decarboxylation [11]. This isomer of the au-
thentic substrate has the sequence of the methyl and pro-
pionate groups on ring A switched, giving the molecule a 
plane of symmetry that is absent in C-III, and also provid-
ing two sequences of substituents that can be recognized at 
the active site. However, the active site model predicts that 
once the fi rst oxidative decarboxylation has occurred, the 
second propionate side chain cannot be correctly orientat-
ed until the intermediate has dissociated from the bind-
ing pocket, fl ipped over, and reentered into the active site. 
This prediction provided a tentative explanation for the 
differences in the observed kinetics using both substrates 
by Jackson et al. [4]. Since C-IV can be processed as a sub-
strate by normal (wildtype) copro’gen oxidase, this would 
result in a divinyl product with a concomitant accumula-
tion of a monovinyl species. We speculate that the accumu-
lation of both the mono- and divinyl products from C-IV 
in the mitochondria could then be correlated with clinical 
symptoms of the patients with harderoporphyria, resulting 
from the defect in a previous enzyme rather than in the 
copro’gen oxidase enzyme. However, the active site model 
was designed from results observed using crude preparations 
of copro’gen oxidase from avian erythrocytes. As yet there 
have been no reports on the kinetics for C-IV metabolism 
using highly purifi ed human enzyme preparations. In this 
work, experiments were performed using purifi ed prepara-
tions of the cloned human enzyme. The kinetic constants 
(Km, Kcat, and Kcat/Km) were determined using non-lin-
ear regression under initial velocity (vo) conditions using 
either C-III or C-IV as substrate.
MATERIAL AND METHODS
Coproporphyrin-IV tetramethyl ester was prepared by the 
cyclization of an a,c-biladiene intermediate following the 
method reported by Lash et al. [10] and coproporphyrin 
III tetramethyl ester was purchased from Aldrich Chemical 
Company. Prior to reduction to the corresponding porphy-
rinogens, they were incubated overnight with 8.3 M HCl to 
remove the methyl esters.
Enzyme assay
Using the micro method of Jones et al. [12], either the C-III 
or C-IV porphyrinogen substrate (at a substrate concentra-
tion of 1 µM) was incubated with copro’gen oxidase at times 
from 15 sec to 30 min. The fi nal reaction volume was 310 
µl which was made up of 300 µl of enzyme in 250 mM imi-
dazole buffer, pH 7.2 and 10 µl of substrate. In another set 
of experiments, substrate concentration was varied from 0 
to 3.5 µM while holding the incubation time constant at 15 
sec. For all reactions, the temperature was 37oC and the en-
zyme was 7.5 µg (0.20 nmoles) per incubate.
The reactions were stopped by addition of 3/7 (v/v) acetic 
acid/ethyl acetate, followed by extraction and Fischer esteri-
fi cation overnight. In all experiments, a zero incubation time 
control (addition of acetic acid/ethyl acetate before addi-
tion of substrate) was performed for comparison. Following 
neutralization and extraction of the porphyrin methyl esters, 
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they were evaluated using normal phase High Performance 
Liquid Chromatography (HPLC; Beckman System Gold). A 
normal phase column (Beckman Silica 5 µ, 4.6 mm × 25 cm) 
was used with 35/65 (v/v) ethyl acetate/cyclohexane at a 
fl ow rate of 1.3 ml per minute; eluates were evaluated spec-
trophotometrically at a wavelength of 404 nm. Data were 
Figure 1.  (A) Oxidative decarboxylation of C-III to P-IX via harderoporphyrinogen. (B) Oxidative decarboxylation of C-IV to P-XIII via a monovinyl 
intermediate.
A
B
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analyzed using the Gold Nouveau Software and reported 
as% product accumulated or subsequently converted to the 
units of Medlock & Dailey [13]. Representative chromato-
grams are shown in Figure 2. Figure 2A shows product for-
mation after zero or 20 minutes of incubation of C-III with 
enzyme. Figure 2B shows product formation after zero or 
20 minutes of incubation of C-IV with copro’gen oxidase. 
In both cases the unreacted substrate, the monovinyl, and 
the divinyl products are well resolved.
Isolation and purifi cation of copro’gen oxidase
The human cloned enzyme was grown in E. coli strain 
BL21(DE3)RIL (Stratagene) overnight at 37°C, with shak-
ing at 250 rpm, in one-liter cultures using a medium con-
sisting of 10 g tryptone, 5 g yeast extract, 10 g NaCl, and 
100 mg ampicillin. Cells were isolated by centrifugation 
(12,000 × g, 10 min) and lysed using the French hydraulic 
pressure cell (20,000 psi). Then the lysate was centrifuged 
at 35,000 × g for 30 minutes to pellet out the insoluble pro-
tein and membranes. The enzyme, which has the 6 his tag, 
was isolated by the Ni2+ affi nity procedure of Medlock and 
Dailey [13]. Protein was analyzed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) using the 
Laemmli method [14] to test the purity and apparent mo-
lecular weight of the enzyme. The Bradford Protein Assay 
[15] was used to evaluate the concentration of the enzyme. 
Bovine Serum Albumin (BSA) was used as the standard.
RESULTS
Highly purifi ed enzyme (30 mg/liter of cell culture) was ob-
tained and only a single band of MW 37,700 Da was observed 
by SDS-PAGE (Figure 3). Figure 4A shows the time depend-
ent accumulation of divinyl, monovinyl, and total products 
after incubation of 7.5 µg purifi ed enzyme with the authen-
tic C-III substrate (1 µM). Total product was calculated as 
the sum of the monovinyl and divinyl products. Figure 4B 
shows the time dependent accumulation of divinyl, monovi-
nyl, and total products after incubation of C-IV under the 
same conditions. These data are the mean of three separate 
experiments. The range of high and low values about the 
mean value was 5%. The data for the apparent linear por-
tion of the lines (vo; % product/min) were evaluated by lin-
ear regression analysis. The initial velocity (vo) for monovi-
nyl product accumulation is about 50 times faster (vo=106 
relative to 2.4) with C-IV than with C-III. The initial veloci-
ty (vo) for divinyl product accumulation is about the same 
(vo=28 relative to 35) with either substrate. C-IV total prod-
uct accumulation reached an asymptote three to four fold 
faster relative to C-III (vo=139 relative to 37). Using either 
substrate, approximately the same fi nal total product accu-
mulation was evident.
Figure 5A shows vo (nmole product/min/pmole enzyme) 
as a function of substrate over a concentration range of 
0.005 to 3.5 µM using C-III. Figure 5B shows vo as a func-
Figure 3.  SDS-PAGE gel to show the purity of the copro’gen oxidase. 
In lane 1 are MW standards (97, 66, 45, 31, and 21 kDa), 
lanes 2 and 3 are the supernatant (1 and 10 µl), lane 4 is 
the Ni2+ column ﬂ ow through (10 µl), and lanes 5 and 6 are 
the elution fractions (10 and 2 µl) containing the puriﬁ ed 
enzyme.
Figure 2.  (A) Representative HPLC Chromatogram for the methyl 
esters of the porphyrin products resulting from incubations 
of C-III with pure copro’gen oxidase enzyme. (B) HPLC 
Chromatogram for incubations with C-IV. Zero time 
(unreacted) peaks shown with a dotted line and porphyrin 
products isolated after incubation with enzyme with a 
solid line. Peak A corresponds to methylene chloride (used 
to dissolve the sample), peak B to protoporphyrin (divinyl 
product), peak C to harderoporphyrin (monovinyl product), 
and peak D to C-III or C-IV (unreacted substrates) in Figure 
2A and 2B, respectively.
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tion of substrate over a concentration range of 0.005 to 
3.5 µM using C-IV. The kinetic constants (Km, Kcat, and 
Kcat/Km), using either substrate, are shown in Table 1. We 
used the Michaelis-Menton assumptions and linear trans-
formation of the data to obtain the kinetic constants, Km 
and Kcat. For the production of monovinyl product there 
is a 5 fold increase in Km when using C-IV as the substrate 
relative to C-III, but more than an 8 fold increase in Kcat 
Substrate Km (µM) Kcat (min-1) Kcat/Km
Monovinyl Product
C-III 0.13 0.20 1.50
C-IV 0.65 1.70 2.60
Divinyl Product
C-III 0.70 3.30 4.70
C-IV 0.83 0.70 0.85
Total Product
C-III 0.68 3.60 5.30
C-IV 0.78 2.60 3.30
Table 1. Kinetic constants of copro’gen oxidase for monovinyl, divinyl, and total product accumulated.
using C-IV relative to C-III. For the divinyl product ac-
cumulated, there was essentially no difference in Km us-
ing either substrate, but almost a 5 fold increase in Kcat 
using C-III relative to C-IV. The total product accumula-
tion (the sum of the mono and divinyl products detected) 
shows about the same Km for either substrate, and a 1.5 
fold difference in Kcat values with C-III giving the higher 
turnover number.
Figure 4.  (A) Time course study with C-III as the substrate showing the time dependency of product accumulation. (B) Time course with C-IV 
showing the time dependency of product accumulation. Triangles represent total product, squares show divinyl product, and circles 
indicate of monovinyl product intermediate accumulation. All values were the mean of three separate experiments. The range of high and 
low values about the mean was 5%.
A B
Figure 5.  Eﬀ ect of substrate concentration on initial velocity (vo). (A) Substrate concentration curve with C-III as substrate. (B) Substrate 
concentration curve with C-IV as substrate. Triangles represent total product, circles show divinyl product, and squares indicate monovinyl 
product intermediate accumulation. The range of high and low values about the mean value of three separate experiments was 5%.
A B
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DISCUSSION
Using purifi ed wildtype human copro’gen oxidase, the re-
sults clearly demonstrate that C-IV is a good substrate for this 
enzyme and binds in the active site with affi nity comparable 
to the normal pathway C-III substrate. This is not surprising 
since C-IV can fi t in either of two orientations that arise from 
its plane of symmetry. Our data indicate that C-IV is a better 
substrate for human enzyme than that of the other species 
tested by Buldain et al. [5]. Jackson et al. [4] reported that 
the monovinyl product from C-IV accumulates to about 40% 
at intermediary times, but was eventually converted to divinyl 
product. Our data show that the monovinyl product accumu-
lates to 45% but was not apparently converted 100% into di-
vinyl product with the human purifi ed enzyme, even up to 
30 minutes of incubation. For divinyl product accumulation, 
C-III results in a higher turnover (larger Kcat) and more cat-
alytic effi ciency (larger Kcat/Km) with about the same bind-
ing affi nity (Km) relative to C-IV. When considering the to-
tal product accumulation, both of the substrates are equally 
processed under vo conditions. From the literature, a range 
of Km values between 0.05 and 47 µM for C-III have been re-
ported for this enzyme [13]. The Km values determined here 
fall within the literature range. Our Km values were obtained 
using highly purifi ed enzyme at a very short incubation time, 
while previous studies were conducted using a variety of en-
zyme sources, enzyme purities, incubation times, and assay 
procedures which may explain the vast range of values.
When the total product accumulation of C-III was compared 
with C-IV as a function of time, the apparent initial velocity us-
ing C-IV was about 3 fold higher than when using C-III. Thus, 
the position of the propionate group on the A ring leads to dif-
ferent kinetics for the fi rst oxidative decarboxylation for both 
substrates. Different kinetics are also evident for the second 
oxidative decarboxylation with the accumulation of the divinyl 
product being much lower when using C-IV; C-IV resulted in a 
5.5 fold lower Kcat/Km value relative to the C-III data.
CONCLUSIONS
These data support the model that there is a limiting step in 
the second oxidative decarboxylation of C-IV. Thus our mod-
el, which predicts that C-IV comes completely out of the ac-
tive site and fl ips over prior to re-entering the active site lead-
ing to divinyl product formation, is reasonable for the human 
form of the enzyme. This then would allow either C-III or C-
IV to compete with the monovinyl intermediate for the active 
site, thus lowering the divinyl product production from either 
porphyrinogen. In vivo, this would increase the time that these 
porphyrinogens reside in the cell especially in the mitochon-
drial compartment where copro’gen oxidase is located [16], 
allowing them to spontaneously oxidize to the porphyrin form 
not utilized by copro’gen oxidase. This could, therefore, in-
crease the severity of the porphyria. Thus detection of monovi-
nyl porphyrins in urine need not only be related to defects in 
the copro’gen oxidase enzyme. Our data do not support or re-
ject any of the proposed mechanisms for the oxidative decar-
boxylations performed by this enzyme [17]. The active site of 
the enzyme has not yet been well established although several 
crystal structures have been published [11]. An X-ray crystal-
lographic structure for copro’gen oxidase has been recently 
solved for the Saccharomyces cerevisiae oxygen dependant form 
of the enzyme, but not the human form [11]. Although the 
authors speculated about which amino acids were involved in 
the active site, this enzyme structure was solved in the absence 
of substrate. This is likely due to the diffi cultly of keeping the 
substrate in the reduced form recognized by the enzyme dur-
ing crystallization. It is not clear whether the active site has yet 
been correctly identifi ed. Thus, the factors infl uencing sub-
strate selectivity are still not completely understood.
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